

Fig. 1. Outline of generating transgenics by rAd.

7. TYH medium: 697.6 mg/100 mL NaCl, 35.6 mg/100 mL KCl, 25.1 mg/100 mL $CaCl_2 \cdot 2H_2O$, 16.1 mg/100 mL KH_2PO_4, 29.3 mg/100 mL $MgSO_4 \cdot 7H_2O$, 210.6 mg/mL $NaHCO_3$, 100 mg/100 mL glucose, 5.5 mg/100 mL Na-pyruvate, 7.5 mg/100 mL penicillin G · potassium salt, 5 mg/100 mL streptomycin sulfate, 50 mg/100 mL 1% phenol red, and 400 mg/100 mL BSA.



Fig. 2. Outline of generating recombinant adenovirus (COS-TPC methods). Ad5, human-Ad type 5; E1A and E1B, deletions of E1A and E1B regions in the adenovirus; open circle, Ad TP (terminal protein); filled circle, pBR322 replication origin, Amp^r, Ampicilline resistant; COS, COS site of λ phage; Ad5-dlX DNA-TPC, a part of adenoviral DNA-terminal protein complex; vertical dashed line, a possible second homologous recombination.

8. WM-EDTA (Whitten's medium supplemented with 0.1 mM EDTA): 514 mg/100 mL NaCl, 36 mg/100 mL KCl, 16 mg/100 mL KH_2PO_4, 29 mg/100 mL $MgSO_4 \cdot 7H_2O$, 190 mg/100 mL $NaHCO_3$, 100 mg/100 mL glucose, 242 mg/100 mL Na-lactate (or 0.37 mL of 60% syrup), 53 mg/100 mL Ca-lactate $\cdot 5H_2O$, 3.5 mg/100 mL Na-pyruvate, 8 mg/100 mL penicillin G · potassium salt, 5 mg/100 mL streptomycin sulfate, 50 mg/100 mL 1% phenol red, and 300 mg/100 mL BSA.
9. 2.5% Avertin, anesthetic (Sigma).
10. Mineral oil (Squibb).
11. Mouth pipet.
12. Needle (26-gauge, 1.3-in).
13. Syringe (1 mL)
14. Transfer pipet prepared from hard glass capillary pulling it to approximately 100-µm internal diameter (for egg transfer) and 200-µm internal diameter (embryo transfer for implantation). Tip of the capillary is fire polished.
15. Tissue culture dishes.
16. Carbon dioxide (5% [v/v]) incubator set at 37°C.
17. Two stereomicroscopes.
18. Fine dissection scissors.
19. Watchmaker's forceps.
20. Blunt forceps.
21. Fiberoptic illuminator.
22. X-gal staining solution for preimplantation embryos: 0.04% 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal), 1 m*M* $MgCl_2$, 10 m*M* potassium ferricyanide, 10 m*M* potassium ferricyanide in phosphate buffer (pH 7.5).
23. X-gal staining solution for embryos at d 11–13.5 of gestation: 0.5 mg/mL 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal), 0.05% NP-40, 1 m*M* $MgCl_2$, 5 m*M* potassium ferricyanide, 5 m*M* potassium ferricyanide in phosphate buffer, pH 7.5.

3. Methods

3.1. In Vitro Fertilization in TYH Medium

1. Superovulate female F1 mice (C57BL/6xC3H or C57BL/6 strain) by an ip injection of 7.5 IU of PMSG followed 48 h later by an injection of 7.5 IU hCG.
2. Collect spermatozoa from the cauda epididymis of mature F1 male mice.
3. Collect unfertilized eggs from the oviducts 16 h after the hCG injection and transfer 50–150 cumulus-enclosed oocytes to 0.2 mL droplets of TYH medium *(8)* under mineral oil.
4. After 2 h of preincubation, inseminate with a small amount of sperm suspension into the TYH medium containing the oocytes. Final sperm concentration should be 150 spermatozoa/µL.
5. Incubate at 37°C in a 5% CO_2 incubator for fertilization.

3.2. Removal of Zona Pellucida in Acidic Ringer's Solution

1. Two hours after insemination, remove the cumulus cells by treatment with hyaluronidase (300 μg/mL in TYH) for 5–10 min. Ensure complete removal of the cumulus cells.
2. To remove the zona pellucida, place the cumulus-free eggs in acidic tyrode solution *(9)* for a few seconds.
3. Immediately rinse the zona-free eggs by transferring through four droplets of WM-EDTA *(10)*.
4. Place the zona-free eggs in a 100 μL droplet of WM-EDTA under mineral oil.
5. Add the virus stock (*see* **Subheading 3.3.1.** for details) solution to the droplets (each containing 40–80 eggs), and incubate at 37°C in a 5% CO_2 atmosphere.

3.3. Adenoviral Infection of the Mouse Eggs

We have tried to assess adenoviral infection of the sperm and eggs at different stages. First, we asked, Can the spermatozoa be infected with an adenovirus? We could not detect transgene expression in eggs fertilized with spermatozoa that had been incubated with rAd, suggesting that Ads fail to infect the spermatozoa. Second, we tested whether the oocytes can be infected by rAd before fertilization. Although oocytes were infected by the rAd, it was difficult to generate embryos by in vitro fertilization. Most eggs showed abnormal development. Finally, we tested the zona-free, fertilized eggs for infection with an rAd. The zona-free fertilized eggs, morulae, and blastocysts could be infected with rAd at high efficiency, and normal embryos with the desired transgene could be obtained successfully.

Infection by rAd is dependent on the viral titer and the incubation time. These conditions vary with the experimental design (e.g., transient expression in early embryos or transgenics) and need to be independently determined for each viral stock (**Table 1**).

Vector design and construction affect the expression level during early development. As in the case of a foreign DNA injected into the eggs, rAd-mediated transgene expression is also dependent on the nature of the transgene. Ad-mediated gene transfer method, however, is almost 100% efficient for the delivery of a foreign DNA into the preimplantation embryos (*also see* **Subheading 4.1.**).

3.3.1. Adenoviral Infection of the Zona-Free Fertilized Eggs

1. For each rAd determine the viral dosage independently. Virus titer ranging between 1×10^7 and 10^8 pfu/mL (up to 10% of the medium) should be tested.
2. In addition to virus titer, standardize the incubation time for infection. Typically, 2–6 h of incubation is sufficient. In the case of incubation time longer than 2 h, aggregates of the zona-free eggs should be dispersed by pipeting every 2 h.

Table 1
Effect of Viral Dose on Expression of *LacZ* Gene and Integration Efficiency[a]

AdexSR4LacZL (viral dosage [pfu/mL])	Zona pellucida	Survival (%) Blastocysts/eggs	X-gal-stained positive embryos (%) Total eggs
0	–	103/124 (83)	0/80 (0)
1×10^1	–	122/143 (85)	2/108 (2)
1×10^3	–	147/167 (89)	6/103 (6)
1×10^5	–	140/167 (84)	64/95 (67)
1×10^7	–	93/87 (84)	64/68 (94)
1×10^7	+	114/136 (96)	0/136 (0)

AxCANLacZ (viral dosage [pfu/mL])	Zona pellucida	Survival (%) Blastocysts/eggs	Survival (%) Fetuses/blastocysts	Integration efficiency (%)
0	–	102/126 (81)	41/81 (51)	ND
1×10^7	–	286/419 (68)	55/273 (20)	2/55 (4)
5×10^7	–	208/358 (58)	32/194 (17)	4/32 (13)
1×10^8	–	232/587 (39)	36/227 (16)	4/36 (10)

[a]Adex4SRLacZL contains the *E. coli LacZ* gene under the control of SRa promoter (SV40 early promoter fused with HTLV-I LTR). AxCANLacZ contains a nuclear localization signal (nls) fused to the *LacZ* gene under the control of CAG promoter (cytomegalovirus IE enhancer, chicken β-actin promoter, and rabbit β-globin poly [A] signal); ND, not determined (+) with zona pellucida; (–) without zona pellucida.

3. After incubation, remove the excess virus by four washes with WM-EDTA.
4. Select the pronuclear stage eggs under a stereomicroscope. Infected-eggs reach the blastocyst stage within 96 h of culture in microdrops.
5. If the embryos attach to the culture dish, wait until the compaction stage to free them from the surface by gentle pipeting. We use a nontreated dish for embryo culture (6-cm embryo culture dish; Corning).

3.3.2. β-Galactosidase Assay (X-Gal Staining)

Efficiency of gene transfer can be checked in the embryos after 96 h of culture. We examined the β-galactosidase activity in the embryos by histochemical staining according to the protocol of Takeda and Toyoda *(11)* with the following modifications.

1. Rinse the embryos twice with phosphate buffer (pH 7.5) containing 4 mg/mL of polyvinylpyrrolidone (PVP-40; Sigma).
2. Fix the embryos with 0.25% glutaraldehyde in phosphate buffer containing 4 mg/mL of PVP for 10 min on ice.
3. After washing twice in phosphate buffer, transfer the embryos into X-gal staining solution (*see* **Subheading 2., item 22**) and incubate overnight at 37°C.

3.4. Transfer of Zona-Free Embryo Into the Uterus

1. Weigh the 2.5-d pseudopregnant foster mother and then anesthetize by ip injection of avertin (0.015 mL of 2.5% arvtin/g of body wt).
2. Load a transfer pipet with 5–10 expanded blastocysts.
3. Expose and hold the top of the uterus with blunt forceps and use a 26-gauge, 1.3-in. needle to make a hole in the uterine wall.
4. Insert the transfer pipet into the uterus through the hole and gently transfer the blastocysts.

3.5. Analysis of Adenoviral DNA and Transgene DNA

To examine the efficiency of adenoviral integration into mouse chromosome, the embryos derived from blastocysts transferred into the uterus of pseudopregnant foster mother are analyzed.

1. Collect embryos with attached placenta at 11.5 and 13.5 d of gestation and wash with PBS.
2. Test the *LacZ* expression of the embryos by X-Gal staining (*see* **Subheading 2., item 23**).
3. Prepare the genomic DNA from the placentas (*see* Chapter 26) for polymerase chain reaction (*see* Chapter 28) and Southern blot analysis (*see* Chapter 27).
4. Use *LacZ* expression and integration efficiency to determine the optimal conditions for generating a transgenic mouse line.
5. Confirm the germline transmission by Southern blot analysis of F1 tail DNA (*see* Chapters 26 and 27).

3.6. Other Applications

Further applications of the approaches described here relate to tissue- and stage-specific conditional transgenesis. When analyzing the molecular mechanisms of a gene function in vivo, one of the most powerful strategies is the use of mutations that confer gain or loss of function. The Cre/*loxP* site-specific recombination system provides one experimental strategy for this purpose. This system can mediate the "on/off" switching of transgene expression in vivo, where overexpression of a given gene can, for example, cause developmental defects. Recently, our colleagues have established a Cre expressing rAd *(13)*, which is able to mediate the switching of gene expression at specific embryo stages and in specific tissues.

Alternatively, conditional transgenesis may be mediated through the use of transgene bearing rAd by direct injection of rAd into the organ of choice in vivo *(14)*. This approach has also been used to deliver tissue-specific expression of gain of function mutants, which are particularly useful tools for the investigation of the molecular basis of vertebrate development *(15,16)*.

4. Notes

1. It is important to check on viral toxicity before starting experiments and to consider the effects of the inserted gene products during early embryo development. Suitable control rAd's such as *LacZ (1)* or *GFP (12)* should be used. The most important parameter of toxicity appears to relate to the fundamental characteristics of viruses generated at high titre. We have noted some toxicity for developing embryos using particularly high viral titres, although other groups have not reported toxic effects even where high titers of virus were used in gene therapy protocols.

Acknowledgments

We wish to thank Dr. Izumu Saito, Dr. Yumi Kanegae, and Dr. Sanae Miyake for generating the recombinant adenoviruses and for critically reading the manuscripts.

References

1. Tsukui, T., Kanegae, Y., Saito, I., and Toyoda, Y. (1996) Transgenesis by adenovirus-mediated gene transfer into mouse zona-free eggs. *Nat. Biotech.* **14,** 982–985.
2. Tsukui, T., Miyake, S., Azuma, S., Ichise, H., Saito, I., and Toyoda, Y. (1995) Gene transfer and expression in mouse preimplantation embryos by recombinant adenovirus vector. *Mol. Reprod. Dev.* **42,** 291–297.
3. Miyake, S., Makimura, M., Kanegae, Y., Harada, S., Sato, Y., Takamori, K., Tokuda, C., and Saito, I. (1996) Efficient generation of recombinant adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. *Proc. Natl. Acad. Sci. USA* **93,** 1320–1324.

4. Kanegae, Y., Lee, G., Sato, Y., Tanaka, M., Nakai, M., Sakaki, T., Sugano, S., and Saito, I. (1995) Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. *Nucleic Acids Res.* **23,** 3816–3821.
5. McGrory, W. J., Bautista, D. S., and Graham, F. L. (1988) A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. *Virology* **163,** 614–617.
6. Stratford-Perricaudet, L. D., et al. (1990) Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. *Hum. Gene Ther.* **1,** 241–256.
7. Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Efficient selection for high expression transfectants with a novel eukaryotic vector. *Gene* **108,** 193–200.
8. Toyoda, Y., Yokoyama, M., and Hosi, T. (1971) Studies on the fertilization of mouse eggs in vitro. *Jpn. J. Anim. Reprod.* **16,** 147–151.
9. Hogan, B., Beddington, R., Constantini, F., and Lancy, E. (1994) *Manipulating the Mouse Enbryo*, 2nd Ed., Cold Spring Laboratory Press.
10. Hoshi, M. and Toyoda, Y. (1985) Effect of EDTA on the preimplantation development of mouse embryos fertilized in vitro. *Jpn. J. Zootech. Sci.* **56,** 931–937.
11. Takeda, S. and Toyoda, Y. (1991) Expression of SV40-lacZ gene in mouse preimplantation embryos after pronuclear microinjection. *Mol. Reprod. Dev.* **30,** 90–94.
12. Tavares, A. T., Tsukui, T., and Izpisua-Belmonte, J. C. (2000) Evidence that members of the Cut/Cux/CDP family may be involved in AER positioning and polarizing activity during chick limb development. *Development* **127,** 5133–5144.
13. Sato, Y., Tanaka, K., et al. (1998) Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. *Biochem. Biophys. Res. Com.* **244,** 455–462.
14. Shibata, H., Noda, T., et al. (1997) Rapid Colorectal Adenoma Formation Initiated by Conditional Targeting of the *Apc* Gene. *Science* **278,** 120–123.
15. Capdevila, J. Tsukui, T., Izpisua-Belmonte, J. C., et al. (1999) Control of vertebrate limb outgrowth by the proximal factor Meis2 and distal antagonism of BMPs by Germline. *Mol. Cell* **4,** 839–849.
16. Rodriguez-Esteban, C., Tsukui, T., Izpisua-Belmonte, C., et al. (1999) The T-box genes Tbx4 and Tbx5 regulate limb outgrowth and identity. *Nature* **398,** 814–818.

THE JOURNAL OF BIOLOGICAL CHEMISTRY
Vol. 278, No. 17, Issue of April 25, pp. 14827–14831, 2003
Printed in U.S.A.

Alleviation of PC4-mediated Transcriptional Repression by the ERCC3 Helicase Activity of General Transcription Factor TFIIH*

Received for publication, December 26, 2002, and in revised form, February 12, 2003
Published, JBC Papers in Press, February 17, 2003, DOI 10.1074/jbc.M213172200

Aya Fukuda‡, Shigeki Tokonabe, Mitsuhiro Hamada, Masahito Matsumoto, Tohru Tsukui, Yasuhisa Nogi, and Koji Hisatake§

From the Department of Molecular Biology, Saitama Medical School, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan

Positive cofactor 4 (PC4), originally identified as a transcriptional coactivator, possesses the ability to suppress promoter-driven as well as nonspecific transcription via its DNA binding activity. Previous studies showed that the repressive activity of PC4 on promoter-driven transcription is alleviated by transcription factor TFIIH, possibly through one of its enzymatic activities. Using recombinant TFIIH, we have analyzed the role of TFIIH for alleviating PC4-mediated transcriptional repression and determined that the excision repair cross complementing (ERCC3) helicase activity of TFIIH is the enzymatic activity that alleviates PC4-mediated repression via β-γ bond hydrolysis of ATP. In addition, the alleviation does not require either ERCC2 helicase or cyclin-dependent kinase 7 kinase activity. We also show that, as complexed within TFIIH, the cyclin-dependent kinase 7 kinase does not possess the activity to phosphorylate PC4. Thus, TFIIH appears to protect promoters from PC4-mediated repression by relieving the topological constraint imposed by PC4 through the ERCC3 helicase activity rather than by reducing the repressive activity of PC4 via its phosphorylation.

Positive cofactor 4 (PC4)[1] was originally identified in the upstream-factor stimulatory activity that augments activator-dependent transcription *in vitro* (1, 2). PC4 stimulates transcription *in vitro* with diverse kinds of activators, including VP16 (3, 4), thyroid hormone receptor (5), octamer transcription factor-1 (6), and BRCA-1 (7), presumably by facilitating assembly of the preinitiation complex through bridging between activators and the general transcriptional machinery (4, 8). Studies on the interaction of PC4 with activators and TFIIA, as well as *in vitro* functional analyses, suggest that interaction between TFIIA and PC4 plays a pivotal role for facilitating the preinitiation complex (PIC) assembly (3, 4). Further studies also demonstrated the importance of PC4 for transcriptional activation by AP-2 (9) and HIV transactivator Tat (10) *in vivo*. In addition, a yeast homologue of PC4, SUB1/TSP1 (11, 12), which is essential for viability in the presence of TFIIB mutations (12), was shown to function as a coactivator for GCN4 and HAP proteins. The N-terminal region of PC4 contains a serine-rich portion termed the SEAC domain, which exhibits similarity to viral immediate-early proteins (3). Phosphorylation of the serine residues in the SEAC domain negatively regulates the coactivator activity of PC4 (3, 13) possibly by a conformational change.

In addition to the role as coactivator, PC4 was subsequently shown to repress promoter-driven transcription as well as nonspecific transcription *in vitro* (14, 15). The analyses of PC4 mutants demonstrated that the repressive activity is a separate function from the coactivator activity (14); therefore, the repressive activity of PC4 may play an as yet unknown function in regulating transcription *in vivo*. In fact, the primary function of PC4 *in vivo* could possibly be to repress transcription rather than to enhance transcription because phosphorylated PC4, which is inactive as a coactivator but retains repressive activity, is the predominant form (~95%) within the cells (13). Transcriptional repression by PC4 correlates with the single-stranded (ss) DNA binding activity present in its C-terminal region, which shows preferential binding to melted double-stranded (ds) DNA and to heteroduplex DNA (14). The structural studies show that PC4 forms a homodimer via its C-terminal region that contains four-stranded β-sheets rich in positively charged and aromatic residues involved directly in binding to ssDNA (16, 17). Interestingly, in contrast to its coactivator activity, the ssDNA binding activity of PC4 is augmented by phosphorylation of its N-terminal region (8). Further studies indicate that PC4-mediated repression of specific transcription from promoters is alleviated by TFIIH, possibly through its enzymatic activities that require β-γ hydrolysis of ATP (14, 15). However, the identity of the enzymatic activity responsible for the alleviation as well as the mechanism by which TFIIH alleviates PC4-mediated repression remains unknown.

Here we used the recombinant TFIIH mutants that lack one of the enzymatic activities (cdk7 kinase, ERCC2 helicase, or ERCC3 helicase) (18) and examined the mechanism by which TFIIH counteracts the repressive effect of PC4. We have found that TFIIH counteracts PC4-mediated repression via ERCC3 helicase activity and that neither ERCC2 helicase nor cdk7 kinase activity is required for alleviating the repression, an observation further supported by the fact that TFIIH does not phosphorylate PC4. Our results suggest that PC4 and the ERCC3 helicase activity of TFIIH may act together to increase the specificity of transcription and also to provide more intricate regulation of transcription.

* This work was supported by grants-in-aid from the Ministry of Education, Science, Sports, and Culture of Japan and by the Maruki Memorial Prize of Saitama Medical School. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "*advertisement*" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ A Research Fellow of the Japan Society for the Promotion of Science.

§ To whom correspondence should be addressed. Tel.: 81-49-276-1490; Fax: 81-49-294-9751; E-mail: kojihisa@saitama-med.ac.jp.

[1] The abbreviations used are: PC4, positive cofactor 4; ERCC, excision repair cross-complementing; cdk, cyclin-dependent kinase; PIC, preinitiation complex; dsDNA, double-stranded DNA; ssDNA, single-stranded DNA; RNAPII, RNA polymerase II; TBP, TATA box-binding protein; CTD, carboxyl-terminal domain; Ni-NTA, nickel-nitrilotriacetic acid; TF, transcription factor; nt, nucleotide; HIV, human immunodeficiency virus.

EXPERIMENTAL PROCEDURES

Purification of Transcription Factors—PC4 was expressed in *Escherichia coli*, BL21(DE3)pLysS, harboring the plasmid pET11c-PC4, and the extract was prepared by sonication in buffer A (20 mM Hepes-KOH, pH 7.9, 10% glycerol, 1 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol containing 100 mM KCl). The extract was applied onto a HiTrap SP column, and the bound proteins were eluted with a 5-column volume of a linear gradient of 0.1–0.6 M KCl. The eluted fractions were diluted to adjust the conductivity to that of 0.1 M KCl and then loaded onto a HiTrap heparin column. The bound proteins were eluted with a 5-column volume of linear gradient of 0.1–0.6 M KCl. RNA polymerase II (RNAPII), TFIIB, TFIIE, TFIIF, and FLAG-tagged TBP (f:TBP) were prepared essentially as described (19).

Preparation of Recombinant TFIIH—Recombinant TFIIH and its mutants were reconstituted in High Five cells using three baculoviruses, each of which expresses three subunits of TFIIH (18, 19). The purification of TFIIH was done essentially as described (19) except that TALON™ metal affinity resin (Clontech) was used in place of Ni-nitrilotriacetic acid (NTA) superflow (Qiagen). The amount of each TFIIH, whose cdk7 subunit is C-terminal-tagged with a FLAG epitope, was adjusted by using silver-stained gels as well as quantitative immunoblots with anti-FLAG M2 antibody.

In Vitro Transcription—*In vitro* transcription reactions were carried out in a 25-μl reaction containing 12 mM Hepes-KOH, pH 7.9, 6% glycerol, 60 mM KCl, 0.6 mM EDTA, 8 mM $MgCl_2$, 5 mM dithiothreitol, 20 units of RNase inhibitor (TaKaRa), 0.2 mM ATP, 0.2 mM UTP, 0.1 mM 3′-*O*-methyl GTP, 12.5 μM CTP, 10 μCi of [α-^{32}P]CTP, 20 ng TFIIA, 10 ng TFIIB, 4 ng f:TBP, 10 ng TFIIE, 20 ng TFIIF, 20 ng recombinant TFIIH, 100 ng RNAPII, and the indicated amount of PC4. All the transcription reactions contained negatively supercoiled pMLΔ53 (100 ng) as a template. The reactions were performed at 30 °C for 1 h, stopped by the addition of 20 mM EDTA, 0.2% SDS, and 5 μg of proteinase K, and further incubated at 37 °C for 1 h. After phenol/chloroform extraction and ethanol precipitation, the transcripts were analyzed by electrophoresis on a 5% denaturing polyacrylamide gel, followed by autoradiography.

Kinase Assays—Phosphorylation of GST-CTD (carboxyl-terminal domain) and PC4 by TFIIH was performed essentially as described (19). Where indicated, casein kinase II (New England Biolabs) was used in place of TFIIH as indicated.

RESULTS

Requirement of β-γ Bond Hydrolysis of ATP for the Alleviation of PC4-mediated Repression by TFIIH—To investigate the functional relationship between TFIIH and PC4, we prepared recombinant TFIIH reconstituted in the insect cells infected with three baculoviruses that expressed TFIIH subunits (18, 19). *In vitro* transcription assays were performed with recombinant TBP, TFIIB, TFIIE, TFIIF, and TFIIH together with RNAPII purified from HeLa cells (Fig. 1*A*), using a linearized pMLΔ53C2AT template that contained the adenovirus major late promoter fused with a 380-bp G-less cassette (19). The specific 390-nt transcript was observed only in the presence of all factors. No transcription was observed when one of the factors was omitted from the reaction, indicating that there was no cross-contamination among the factors (Fig. 1*B*).

We next tested whether recombinant TFIIH could alleviate transcriptional repression by PC4. As shown in Fig. 2*A*, even in the absence of TFIIH, the negatively supercoiled template allowed production of the specific 390-nt transcript (*lane 1*), which was suppressed to less than 5% by the addition of PC4 (*lane 2*). Adding the increasing amounts of TFIIH, however, gradually restored the levels of transcription (*lanes 3–6*) to 40–60% of those seen in the absence of both TFIIH and PC4 (*lane 1*), indicating that recombinant TFIIH can reverse the repressive effect of PC4 in a dose-dependent manner as does natural TFIIH (14, 15).

Using the highly purified reconstituted system, we then tested the requirement for β-γ bond hydrolysis by substituting ATP with adenylyl-imidodiphosphate (AMP-PNP) and adenosine-5′-*O*-(thiotriphosphate) (ATP-γS), both of which can be incorporated into growing RNA chains during transcription but



FIG. 1. **Transcription factors used for *in vitro* transcription.** *A*, purified proteins were separated by 10% SDS-PAGE and silver stained. *B*, reconstituted transcription analysis *in vitro*. Transcription reactions were performed with a linearized pMLΔC2AT that requires TFIIH for the production of the 390-nt-specific transcript. Transcription assays were performed in the presence of all factors (*lane 1*) or in the absence of TBP (*lane 2*), TFIIB (*lane 3*), TFIIE (*lane 4*), TFIIF (*lane 5*), TFIIH (*lane 6*), or RNAPII (*lane 7*). The *arrow* indicates the position of the 390-nt transcript.



FIG. 2. **Requirement of β-γ bond hydrolysis of ATP for alleviating PC4-mediated repression by TFIIH.** *A*, recombinant TFIIH was used for alleviating PC4-mediated transcriptional repression. Transcription reactions consisting of TBP, TFIIB, TFIIE, TFIIF, and RNAPII contained 200 ng of PC4 (*lanes 2–6*) together with 5 (*lane 3*), 10 (*lane 4*), 20 (*lane 5*), or 40 ng (*lane 6*) of TFIIH. The *arrow* indicates the position of the 390-nt transcript from pMLΔC2AT. *B*, transcription reactions contained TBP, TFIIB, TFIIE, TFIIF, and RNAPII, with (*lanes 1–7*) or without TFIIH and PC4 (*lanes 8–14*). The reactions also contained 100 μM ATP (*lanes 1* and *8*), no ATP (*lanes 2* and *9*), 100 μM dATP (*lanes 3* and *10*), 100 μM AMP-PNP (*lanes 4* and *11*), 100 μM AMP-PNP and 100 μM dATP (*lanes 5* and *12*), 100 μM ATP-γS (*lanes 6* and *13*), or 100 μM ATP-γS and 100 μM dATP (*lanes 7* and *14*).

cannot be hydrolyzed at the β-γ bond. When ATP was replaced by non-hydrolyzable AMP-PNP or ATP-γS in the transcription reactions containing both PC4 and TFIIH, virtually no transcription was observed (Fig. 2*B*, *lanes 4* and *6*), indicating that β-γ bond hydrolysis of ATP was absolutely required for counteracting PC4-mediated repression. Transcription was restored, however, when AMP-PNP and ATP-γS were further supplemented with dATP (Fig. 2*B*, *lanes 5* and *7*), which could provide β-γ bond hydrolysis. These results show the require-



FIG. 3. **Requirement of ERCC3 helicase activity for alleviating PC4-mediated repression.** *A*, diagram of cdk7, ERCC3, and ERCC2, indicating portions of amino acid sequences including alanine residues (*boldfaced*) that were introduced in place of lysine. The lysine residues (residues 41, 346, and 48 of cdk7, ERCC3, and ERCC2, respectively) in the conserved ATP binding domains, as shown in *filled boxes*, were mutated to alanine using oligonucleotide-directed mutagenesis. *B*, purified recombinant wild-type TFIIH (*WT*) and TFIIH mutants that have a mutation in cdk7 (*K41A*), ERCC3 (*K346A*), or in ERCC2 (*K48A*). *C*, alleviation of PC4-mediated repression requires ERCC3 helicase activity. The transcription reactions contained TBP, TFIIB, TFIIE, TFIIF, PC4, and RNAPII, together with 5, 10, 20, and 40 ng of wild-type TFIIH (*lanes 3–6*), K41A (*lanes 7–10*), K346A (*lanes 11–14*), or K48A (*lanes 15–18*) as indicated.



FIG. 4. **Phosphorylation of PC4.** *A*, phosphorylation of GST-CTD by casein kinase II (*CKII*) and TFIIH were tested. Phosphorylation reactions contained GST-CTD as a substrate together with 2 (*lane 1*) and 10 (*lane 2*) units of casein kinase II or with 100 ng of wild-type TFIIH (*lane 4*), K41A (*lane 5*), K346A (*lane 6*), and K48A (*lane 7*). The *arrows* indicate the position of hyperphosphorylated (*IIO*) and hypophosphorylated (*IIA*) forms of GST-CTD. *B*, phosphorylation reactions contained casein kinase II and TFIIH mutants as shown in *panel A*, with 200 ng of PC4 as a substrate in place of GST-CTD. The *top* and *middle panels* show the short (1.5 h) and long exposures (20 h) of the autoradiogram; the *bottom panel* shows Coomassie Blue staining of the same gel. The *arrows* indicate the positions of the phosphorylated (*p-PC4*) and non-phosphorylated (*PC4*) forms of PC4, which migrated as ~20 and ~15 kDa, respectively.

ment for β-γ bond hydrolysis of ATP (or dATP) for alleviating PC4-mediated repression even in the highly pure transcription system. Because TFIIH is the only known factor that utilizes β-γ bond hydrolysis of ATP in this well defined transcription system, the results clearly demonstrate the involvement of the enzymatic activities of TFIIH in the alleviation.

The ERCC3 Helicase Activity of TFIIH Is Essential for Alleviating PC4-mediated Repression—The requirement of β-γ bond hydrolysis suggested that one of the enzymatic activities of TFIIH was required for alleviating the repression by PC4. To determine which enzymatic activity of TFIIH was responsible for the alleviation, we utilized three recombinant TFIIH mutants, each of which is defective in either cdk7 kinase, ERCC3 helicase, or ERCC2 helicase activities (Fig. 3, *A* and *B*). These mutants have alanine instead of the conserved lysine within the ATP binding site of Walker type A motifs, at the 41st residue of cdk7, 346th residue of ERCC3, and 48th residue of ERCC2, respectively (Fig. 3*A*) (18, 20). Substitution of the lysine with either arginine or alanine in these motifs is known to eliminate the ability to hydrolyze ATP, resulting in the inactivation of each enzymatic activity. As shown in Fig. 3*C*, TFIIH with the mutated cdk7 kinase (K41A) and with the mutated ERCC2 helicase (K48A) alleviated PC4-mediated repression as well as wild-type TFIIH, whereas TFIIH with the mutated ERCC3 helicase (K346A) could not alleviate the repression at all. These results demonstrate that ERCC3 helicase activity is the sole enzymatic activity required for alleviating PC4-mediated repression, and neither the cdk7 kinase nor the ERCC2 helicase plays any role in alleviating PC4-mediated repression through ATP hydrolysis.

TFIIH Does Not Phosphorylate PC4—Because the previous result showed that PC4 is released from the template upon phosphorylation by TFIIH (21), the dispensability of the cdk7 kinase for PC4-mediated repression was somewhat unexpected. Furthermore, lack of any consensus phosphorylation site for cdks (*S/TPXR/K*) in PC4 prompted us to re-address whether TFIIH is indeed able to phosphorylate PC4 *in vitro* as previously reported (15, 21). As shown in Fig. 4*A*, wild-type TFIIH, K48A, and K346A phosphorylated CTD efficiently but K41A did not phosphorylate CTD, indicating that the substitution of lysine with alanine at the 41st residue of cdk7 eliminated the kinase activity to an undetectable level. Phosphorylation of CTD by TFIIH produced the hypophosphorylated form as well as the hyperphosphorylated form that showed a slower migration on the SDS gel (Fig. 4*A*). Casein kinase II also phosphorylated CTD, although phosphorylation did not shift the migration of GST-CTD (Fig. 4*A*, *lanes 1* and *2*).

We next tested whether casein kinase II and the same set of TFIIH mutants could phosphorylate PC4. Casein kinase II efficiently phosphorylated PC4 as previously reported (3, 13) and altered PC4 from the faster migrating form (~15 kDa) to the slower migrating form (~20 kDa) (Fig. 4*B*, *bottom panel*, *lanes 1* and *2*). In contrast, wild-type TFIIH, K346A, and K48A, all of which retain cdk7 kinase activity (Fig. 4*A*, *lanes 4*, *6*, and *7*), did not phosphorylate PC4 (Fig. 4*B*, *lanes 4*, *6*, and *7*). The low levels of PC4 labeling observed on a longer exposure of the gel (Fig. 4*B*, *middle panel*, *lanes 3–7*) is not because of the TFIIH kinase activity because the TFIIH mutant K41A, which lacks the kinase activity (Fig. 4*A*, *lane 5*), showed the same degree of labeling as wild-type TFIIH. Our results demonstrate that TFIIH does not phosphorylate PC4 and argue against the involvement of PC4 phosphorylation by TFIIH for alleviating PC4-mediated repression of transcription.

Quantitative Analysis of PC4-mediated Repression in the Absence of the ERCC3 Helicase Activity—The *in vivo* concentration of PC4 is estimated to be ~1 μM in HeLa cells, and ~95% of PC4 is phosphorylated *in vivo*, presumably by casein kinase II (3, 13, 14). Therefore, we tested whether phosphorylated and non-phosphorylated PC4 can distinguish the presence and ab-



FIG. 5. **Repression of transcription by phosphorylated and non-phosphorylated PC4 in the absence of the ERCC3 helicase activity.** The relative levels of transcription are shown. The level of transcription in the absence of PC4 was arbitrarily defined as 1.0. Transcription reactions contained TBP, TFIIB, TFIIE, TFIIF, and RNAPII in the presence of either wild-type TFIIH (*WT*) or the ERCC3-deficient TFIIH mutant (*K346A*), together with indicated amounts of either non-phosphorylated or phosphorylated PC4. The values indicate the level of transcription in the presence of wild-type TFIIH and non-phosphorylated PC4 (*filled squares, solid line*), wild-type TFIIH and phosphorylated PC4 (*open squares, dotted line*), K346A and non-phosphorylated PC4 (*filled triangles, solid line*), and K346A and phosphorylated PC4 (*open triangles, dotted line*).



FIG. 6. **Model for PC4 in the regulation of transcription from non-promoter and promoter regions.** *A*, PC4 binds to dsDNA and ssDNA regions and prevents the binding of RNAPII to ssDNA regions by a direct competition. PC4 bound to dsDNA regions may also serve as a reservoir for PC4 recruited to ssDNA regions. *B*, PC4 binds dsDNA regions and prevents the binding of RNAPII to DNA by restricting the formation of transient ssDNA regions. *C*, the PIC (*dotted line*) containing TFIIH can initiation transcription from the promoter DNA that is bound by PC4. *D*, the PIC whose TFIIH activity is repressed (such as by FBP interacting repressor) fails to initiate transcription from the promoter DNA that is bound by PC4.

sence of ERCC3 helicase activity within the general transcriptional machinery at the physiological PC4 concentration. PC4 was first phosphorylated by CKII as shown in Fig. 4*B*, and then increasing amounts of both phosphorylated and non-phosphorylated PC4 were added to the transcriptional reactions containing either wild-type TFIIH or K346A. As shown in Fig. 5, the levels of transcription were reduced to less than 40% at 0.125 μM of PC4 and to ~10% at 1 μM of PC4 in the absence of ERCC3 helicase activity. Non-phosphorylated PC4 repressed transcription slightly better than phosphorylated PC4 in the absence of ERCC3 helicase activity (Fig. 5). By contrast, in the presence of wild-type TFIIH, transcription remained markedly more resistant to repression by PC4 (Fig. 5) (14). These results indicate that PC4 represses transcription regardless of its phosphorylation status in the absence of ERCC3 helicase activity. In addition, because repression by PC4 occurs similarly in the presence of K346A (Fig. 5) as in the absence of TFIIH (data not shown) (14), mutual exclusion of PC4 and TFIIH on the promoter is an unlikely mechanism for the antagonistic effect of PC4 and TFIIH.

DISCUSSION

Our results show that the ERCC3 helicase activity of TFIIH counteracts PC4-mediated transcriptional repression and that neither the ERCC2 helicase nor the cdk7 kinase has any role in this process. The fact that the ERCC3 helicase, but not the cdk7 kinase, of TFIIH relieves PC4-mediated repression provides a clue as to the mechanism by which TFIIH and PC4 act antagonistically to regulate transcription. Negatively supercoiled templates allow specific transcription by RNAPII in the absence of TFIIH and ATP *in vitro* (22, 23), presumably by the transfer of free energy stored on the negatively supercoiled templates (24–26). This transfer of free energy appears to be constrained by PC4, because the property of negatively supercoiled DNA templates bound by PC4 is similar to that of linear DNA templates with regard to the absolute requirement of TFIIH and ATP for specific promoter-driven transcription (22, 23). This effect of PC4 transmitted indirectly through DNA to the general transcriptional machinery is consistent with the functional antagonism between TFIIH and PC4 that does not involve the mutual exclusion of TFIIH and PC4 on the promoter (Fig. 5). Thus, the role for ERCC3 helicase activity may be to overcome the topological constraint conferred by PC4 on negatively supercoiled templates, a process that could potentially prompt the release of PC4 from the promoter region (21). Our results, however, rule out the possibility that the cdk7 kinase of TFIIH phosphorylates PC4 (15, 21) and facilitates its release from the promoter (21).

In light of our study as well as a previous study (14), we propose two possible mechanisms by which PC4 represses promoter-independent transcription: *i.e.* "direct" and "indirect" mechanisms. In the direct mechanism, PC4 binds to ssDNA regions via its ssDNA binding ability, competing directly with RNAPII, and thus physically displaces RNAPII from ssDNA regions (Fig. 6*A*). By contrast, in the indirect mechanism PC4 binds dsDNA regions via its dsDNA binding ability and renders DNA more "rigid" so that the free energy stored in negative superhelicity (24–26) will not generate transiently melted ssDNA regions that permit RNAPII to initiate random transcription (Fig. 6*B*). It is conceivable that the indirect mechanism provides the primary protection against spurious transcription and the direct mechanism provides a backup. In this scenario, PC4 bound to dsDNA regions may also serve as a reservoir that can be recruited quickly to ssDNA regions where the possibility of spurious transcription is greater. In agreement with the recruitment of PC4 from dsDNA to ssDNA, PC4 binds to ssDNA more strongly than to dsDNA (14).

PC4-mediated repression of transcription from non-promoter regions as described above may facilitate the efficient allocation of the limiting amount of RNAPII *in vivo* (27, 28), which could be otherwise sequestered onto transiently melted ssDNA regions. In the living cells, DNA is predominantly negatively supercoiled and is also undergoing dynamic topological changes during DNA replication, transcription, and repair, possibly exposing melted ssDNA regions frequently. Spurious transcription from these melted ssDNA regions is likely to be suppressed mainly by phosphorylated PC4, which constitutes ~95% of PC4 *in vivo* (13), because phosphorylated PC4 can strongly suppress promoter-independent (and thus, general transcription factor-independent) transcription from the melted DNA region *in vitro* (14).

PC4 may also play a role in preventing spurious transcription from promoters, which *in vivo* is likely to be negatively supercoiled and from which transcription could be potentially initiated in the absence of TFIIH. When the ERCC3 helicase of

TFIIH is active within the general transcriptional machinery, transcription is probably not repressed by PC4 *in vivo* (Fig. 6*C*) because the TFIIH ERCC3 helicase activity counteracts the repressive activity of phosphorylated PC4 at the physiological concentration (~1 μM) (Fig. 5). Indeed, when PC4 is overexpressed in cells in the absence of the HIV transactivator, transcription from the HIV promoter is only marginally reduced or not reduced at all, depending upon the assay conditions (10). However, if the ERCC3 helicase activity of TFIIH is inhibited (Fig. 5), such as by negative regulator of activated transcription and by FBP interacting repressor (29, 30), phosphorylated PC4 may further reduce the low background transcription from promoters even at the physiological PC4 concentration (Fig. 6*D*). Because TFIIH appears to be sub-stoichiometric (20–30%) to other general transcription factors *in vivo* (27), a fraction of PIC might even lack TFIIH and could be repressed by PC4, though this possibility must be rigorously examined *in vivo*. In any event, regulation of promoter-dependent transcription with a high level of dynamic range *in vivo* is likely to be contingent upon the presence of PC4, because negatively supercoiled DNA *in vivo* may permit inadvertent transcription from promoters and could potentially reduce the dynamic range of transcriptional regulation.

Several lines of evidence suggest the importance of PC4 in regulating transcription *in vivo*. First, a yeast homolog of human PC4, SUB4, enhances transcriptional activation by the activators GCN5 and HAP4 (12), and though PC4 is not essential for viability, its deletion results in inositol auxotrophy, a phenotype observed in the mutations of transcriptional regulators such as SNF/SWI, SRB, and the CTD of RNA polymerase II (31–34). Second, PC4 enhances TAT-dependent transcription from the HIV promoter (10) and restores the reduced AP-2 activity in the *ras*-transformed cell lines by relieving AP-2 self-interference (9). Finally, PC4 may play a role as a tumor suppressor in lung and bladder cancers, because the loss of heterogeneity of the PC4 gene is often observed in these cancer cells (35, 36). These results demonstrate the importance of PC4 as a regulator of transcription and possibly as a tumor suppressor *in vivo*. Though the importance of PC4 *in vivo* has been mainly interpreted in the context of its coactivator activity, the predominance of the repressive form of PC4 *in vivo* (13) suggests that some of the observed effects may well be attributed to the reduced precision of transcriptional regulation caused by the loss of the repressive activity of PC4.

In conclusion, the repressive activity of PC4 may be essential for the intricate regulation of transcription in conjunction with the ERCC3 helicase of TFIIH. The repressive activity of PC4, and possibly of other ssDNA-binding proteins, may play an important but yet under-appreciated role for more elaborate and fine-tuned regulation of reactions involving DNA molecules.

Acknowledgment—We thank M. Suganuma for technical assistance.

REFERENCES

1. Meisterernst, M., Roy, A. L., Lieu, H. M., and Roeder, R. G. (1991) *Cell* **66,** 981–993
2. Kaiser, K., and Meisterernst, M. (1996) *Trends Biochem. Sci.* **21,** 342–345
3. Kretzschmar, M., Kaiser, K., Lottspeich, F., and Meisterernst, M. (1994) *Cell* **78,** 525–534
4. Ge, H., and Roeder, R. G. (1994) *Cell* **78,** 513–523
5. Fondell, J. D., Guermah, M., Malik, S., and Roeder, R. G. (1999) *Proc. Natl. Acad. Sci. U. S. A.* **96,** 1959–1964
6. Luo, Y., Ge, H., Stevens, S., Xiao, H., and Roeder, R. G. (1998) *Mol. Cell. Biol.* **18,** 3803–3810
7. Haile, D. T., and Parvin, J. D. (1999) *J. Biol. Chem.* **274,** 2113–2117
8. Kaiser, K., Stelzer, G., and Meisterernst, M. (1995) *EMBO J.* **14,** 3520–3527
9. Kannan, P., and Tainsky, M. A. (1999) *Mol. Cell. Biol.* **19,** 899–908
10. Holloway, A. F., Occhiodoro, F., Mittler, G., Meisterernst, M., and Shannon, M. F. (2000) *J. Biol. Chem.* **275,** 21668–21677
11. Henry, N. L., Bushnell, D. A., and Kornberg, R. D. (1996) *J. Biol. Chem.* **271,** 21842–21847
12. Knaus, R., Pollock, R., and Guarente, L. (1996) *EMBO J.* **15,** 1933–1940
13. Ge, H., Zhao, Y., Chait, B. T., and Roeder, R. G. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91,** 12691–12695
14. Werten, S., Stelzer, G., Goppelt, A., Langen, F. M., Gros, P., Timmers, H. T., Van der Vliet, P. C., and Meisterernst, M. (1998) *EMBO J.* **17,** 5103–5111
15. Kershnar, E., Wu, S.-Y., and Chiang, C.-M. (1998) *J. Biol. Chem.* **273,** 34444–34453
16. Brandsen, J., Werten, S., van der Vliet, P. C., Meisterernst, M., Kroon, J., and Gros, P. (1997) *Nat. Struct. Biol.* **4,** 900–903
17. Werten, S., Wechselberger, R., Boelens, R., van der Vliet, P. C., and Kaptein, R. (1999) *J. Biol. Chem.* **274,** 3693–3699
18. Fukuda, A., Nogi, Y., and Hisatake, K. (2002) *Proc. Natl. Acad. Sci. U. S. A.* **99,** 1206–1211
19. Fukuda, A., Yamauchi, J., Wu, S.-Y., Chiang, C.-M., Muramatsu, M., and Hisatake, K. (2001) *Genes Cells* **6,** 707–719
20. Wada, T., Orphanides, G., Hasegawa, J., Kim, D. K., Shima, D., Yamaguchi, Y., Fukuda, A., Hisatake, K., Oh, S., Reinberg, D., and Handa, H. (2000) *Mol. Cell* **5,** 1067–1072
21. Malik, S., Guermah, M., and Roeder, R. G. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95,** 2192–2197
22. Parvin, J. D., and Sharp, P. A. (1993) *Cell* **73,** 533–540
23. Goodrich, J. A., and Tjian, R. (1994) *Cell* **77,** 145–156
24. Lilley, D. M. (1988) *Trends Genet.* **4,** 111–114
25. Murchie, A. I., Bowater, R., Aboul-ela, F., and Lilley, D. M. (1992) *Biochim. Biophys. Acta* **1131,** 1–15
26. Holstege, F. C., Tantin, D., Carey, M., van der Vliet, P. C., and Timmers, H. T. (1995) *EMBO J.* **14,** 810–819
27. Borggrefe, T., Davis, R., Bareket-Samish, A., and Kornberg, R. D. (2001) *J. Biol. Chem.* **276,** 47150–47153
28. Kimura, M., Sakurai, H., and Ishihama, A. (2001) *Eur. J. Biochem.* **268,** 612–619
29. Akoulitchev, S., Chuikov, S., and Reinberg, D. (2000) *Nature* **407,** 102–106
30. Liu, J., He, L., Collins, I., Ge, H., Libutti, D., Li, J., Egly, J. M., and Levens, D. (2000) *Mol. Cell* **5,** 331–341
31. Peterson, C. L., and Herskowitz, I. (1992) *Cell* **68,** 573–583
32. Peterson, C. L., Dingwall, A., and Scott, M. P. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91,** 2905–2908
33. Thompson, C. M., Koleske, A. J., Chao, D. M., and Young, R. A. (1993) *Cell* **73,** 1361–1375
34. Cairns, B. R., Kim, Y. J., Sayre, M. H., Laurent, B. C., and Kornberg, R. D. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91,** 1950–1954
35. Wieland, I., Bohm, M., Arden, K. C., Ammermuller, T., Bogatz, S., Viars, C. S., and Rajewsky, M. F. (1996) *Oncogene* **12,** 97–102
36. Bohm, M., Kirch, H., Otto, T., Rubben, H., and Wieland, I. (1997) *Int. J. Cancer* **74,** 291–295

MOLECULAR AND CELLULAR BIOLOGY, July 2004, p. 6525–6535 Vol. 24, No. 14
0270-7306/04/$08.00+0 DOI: 10.1128/MCB.24.14.6525–6535.2004

Transcriptional Coactivator PC4 Stimulates Promoter Escape and Facilitates Transcriptional Synergy by GAL4-VP16

Aya Fukuda,[1]† Tomoyoshi Nakadai,[1] Miho Shimada,[1] Tohru Tsukui,[1] Masahito Matsumoto,[1] Yasuhisa Nogi,[1] Michael Meisterernst,[2] and Koji Hisatake[1]*

Department of Molecular Biology, Saitama Medical School, Moroyama, Iruma-gun, Saitama 350-0495, Japan,[1] and Gene Expression, Institute of Molecular Immunology, GSF-National Research Center for Environment and Health, Munich, Germany[2]

Received 24 December 2003/Returned for modification 18 January 2004/Accepted 14 April 2004

Positive cofactor 4 (PC4) is a coactivator that strongly augments transcription by various activators, presumably by facilitating the assembly of the preinitiation complex (PIC). However, our previous observation of stimulation of promoter escape in GAL4-VP16-dependent transcription in the presence of PC4 suggested a possible role for PC4 in this step. Here, we performed quantitative analyses of the stimulatory effects of PC4 on initiation, promoter escape, and elongation in GAL4-VP16-dependent transcription and found that PC4 possesses the ability to stimulate promoter escape in response to GAL4-VP16 in addition to its previously demonstrated effect on PIC assembly. This stimulatory effect of PC4 on promoter escape required TFIIA and the TATA box binding protein-associated factor subunits of TFIID. Furthermore, PC4 displayed physical interactions with both TFIIH and GAL4-VP16 through its coactivator domain, and these interactions were regulated distinctly by PC4 phosphorylation. Finally, GAL4-VP16 and PC4 stimulated both initiation and promoter escape to similar extents on the promoters with three and five GAL4 sites; however, they stimulated promoter escape preferentially on the promoter with a single GAL4 site. These results provide insight into the mechanism by which PC4 permits multiply bound GAL4-VP16 to attain synergy to achieve robust transcriptional activation.

Transcription of mRNA-coding genes involves RNA polymerase II and six general transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) which comprise the basal transcription machinery that recognizes the core promoter elements and elicits the basal level of transcription (50). Activated transcription requires the binding of activators to the regulatory DNA sequences typically present upstream of the core promoter and their interactions with the general transcription machinery (32, 49). Despite the well-documented direct interactions of activators with the general transcription factors and RNA polymerase II, activated transcription requires yet another group of transcription factors, termed mediators or coactivators, that confer on the general transcription machinery a markedly enhanced responsiveness to activators (2, 18, 20, 36, 41).

A wide array of coactivators may be grouped into two broad categories according to the requirement of chromatin for their action in biochemical assays. The coactivators which function on the templates without chromatin include the TATA box binding protein-associated factors (TAFs) present in TFIID (58), positive cofactors (PCs) (PC1, PC2, PC3, and PC4) derived from the upstream factor stimulatory activity (USA) cofactor fraction (20), and metazoan multiprotein complexes that are structurally related to the yeast mediator (40) (TRAP/SMCC, ARC, DRIP, NAT, murine mediator, human mediator, CRSP, and PC2) (36, 41). The coactivators which require chromatin templates for their functions include CBP/p300, PCAF and its related GCN5 proteins, and p160 family proteins that display histone acetyltransferase activities (4, 65). Given their structural complexity and diversity, these coactivators are expected to show not only redundancy and cooperativity but activator and promoter selectivity as well, posing significant challenges for complete understanding of the various mechanisms by which coactivators facilitate transcription.

One way to approach the mechanisms of coactivator functions is to employ a well-defined transcription system that supports activated transcription in response to the smallest possible numbers of activators and coactivators and to identify the steps of transcription that are targeted physically and functionally by the activators and coactivators. A system well suited for this minimalist approach would be the transcription system that allows activated transcription in response to GAL4-VP16 or other GAL4-derivatives in the presence of coactivator PC4. PC4 is a coactivator that was initially identified in the USA fraction that enhances transcription by various transcriptional activators in vitro (13, 27, 38) and turned out to be identical to the 15-kDa single-stranded DNA (ssDNA)-binding protein. Although PC4 possesses both ssDNA- and double-stranded DNA (dsDNA)-binding activities, which are important for transcriptional repression, only its dsDNA-binding activity appears to correlate with the coactivator activity (62, 63). The coactivator activity of PC4 and its interaction with activators, but not the ssDNA-binding activity, are lost upon phosphorylation of the serine residues within its N-terminal region by casein kinase II (14, 27).

* Corresponding author. Mailing address: Department of Molecular Biology, Saitama Medical School, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan. Phone: 81-49-276-1490. Fax: 81-49-294-9751. E-mail: kojihisa@saitama-med.ac.jp.

† Present address: Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, NY 10021.

Since PC4 interacts with both transcriptional activators and TFIIA (13, 16) and also with TFIIB in the case of its yeast homolog, SUB1/TSP1 (16, 23), PC4 is proposed to promote the assembly of the preinitiation complex (PIC) (13, 21, 27) in activated transcription. However, given that transcription is a multistep process consisting of PIC assembly, promoter opening, initiation, promoter escape, elongation, and reinitiation, steps other than PIC assembly are potential targets for regulation as well. Indeed, despite predominant effects of activators—presumably in conjunction with coactivators—on PIC assembly, the effects on the subsequent steps (1, 28, 31, 37) have also been demonstrated in various systems, including promoter opening (60), promoter escape (10, 29), elongation (66), and reinitiation (26, 67). However, the relative contributions of activators and coactivators in stimulating individual steps of transcription remain to be more clearly defined.

In this study, we have systematically analyzed the stimulatory effects of GAL4-VP16 and PC4 and assigned their quantitative contributions to the stimulation of individual steps of transcription. Our results show that PC4 contributed to the stimulation of promoter escape as well as initiation in the presence of GAL4-VP16 and that these effects were contingent upon the presence of TFIIA and TAFs in TFIID. Consistent with the previously demonstrated requirement of the ERCC3 helicase activity of TFIIH in stimulating promoter escape (10), PC4 was found to interact specifically with TFIIH through its coactivator domain, a region that also interacted with GAL4-VP16. Furthermore, the number of GAL4 sites (and thus the number of bound GAL4-VP16 dimers) on the promoter influenced the degree of stimulation of each step by PC4, revealing possible links between the physical interactions involving PC4 and their functional consequences on the steps of transcription. Together, these results provide important clues as to the mechanism by which PC4 assists GAL4-VP16 in transcriptional activation.

MATERIALS AND METHODS

DNA templates for in vitro transcription. DNA templates pG1HMC2AT and pG3HMC2AT were created by replacement of the five GAL4-binding sites of pG5HMC2AT with the annealed oligonucleotides. The following synthetic oligonucleotides were used for one and three GAL4-binding sites: 5′-AATTCGA GCTCGGTACCAGGGGACTAGAGTCTCCGCTCGGAGGACAGTACTCC GACCTGCA-3′ and 5′-GGTCGGAGTACTGTCCTCCGAGCGGAGACTCT AGTCCCCTGGTACCGAGCTCG-3′, respectively, for pG1HMC2AT and 5′-AATTCGAGCTCGGTACCAGGGGACTAGAGTCTCCGCTCGGAGGACA GTACTCCGCTCGGAGGACAGTACTCCGCTCGGAGGACAGTACTC CGACCTGCA-3′ and 5′-GGTCGGAGTACTGTCCTCCGAGCGGAGTACTG TCCTCCGAGCGGAGTACTGTCCTCCGAGCGGAGACTCTAGTCCCCTGG TACCGAGCTCG-3′, respectively, for pG3HMC2AT. The mixtures of the complementary oligonucleotides were denatured at 90°C for 5min and were then cooled slowly to room temperature in 10 mM Tris-HCl (pH 8.0)–1 mM EDTA–50 mM NaCl. Then, the annealed oligonucleotides were used to replace the EcoRI-PstI fragment encompassing the five GAL4-binding sites of pG5HMC2AT. The obtained DNA templates were sequenced completely on both strands to rule out the possibility of spurious mutations.

Purification of transcription factors and in vitro transcription assays. Purification of recombinant factors (TFIIA, TFIIB, TFIIE, TFIIF, TFIIH, and GAL4-VP16), epitope-tagged TFIID, and RNA polymerase II were performed as described previously (10, 12). Recombinant PC4 was purified as described previously (11). For 390- and 20-nucleotide (nt) transcripts, in vitro transcription reaction mixtures (25 μl) contained 50 ng of negatively supercoiled pG5HMC2AT or its derivative, 12 mM HEPES-KOH (pH 7.9), 6% glycerol, 60 mM KCl, 0.6 mM EDTA, 8 mM $MgCl_2$, 5 mM dithiothreitol (DTT), 20 U of RNase inhibitor (TaKaRa), 0.2 mM ATP, 0.2 mM UTP, 0.1 mM 3′-*o*-methyl GTP, 12.5 μM CTP, 10 μCi of [α-^{32}P]CTP, 20 ng of TFIIA, 10 ng of TFIIB, 1 μl of FLAG-tagged TFIID (which corresponds to ~0.1 ng of TATA binding protein [TBP]), 10 ng of TFIIE, 20 ng of TFIIF, 20 ng of recombinant TFIIH, and 100 ng of RNAPII. Where indicated, the reaction mixtures contained 25 ng of GAL4-VP16 and 200 ng of PC4 as well. Transcription reactions for the initiation product were performed as described previously (10), and the derived pppApC was treated with calf intestinal phosphatase to form ApC before electrophoresis (29). After electrophoresis, the transcripts were quantified by using a Fujix Bas2000 bioimaging analyzer. Stimulation of promoter escape (*n*-fold) was calculated by dividing the stimulation of the 20G transcript (*n*-fold) by that of ApC. Similarly, stimulation of elongation (*n*-fold) was calculated by dividing the stimulation of the 390-nt transcript (*n*-fold) by that of the 20G transcript.

Preparation of PC4-GST. The coding region of PC4 was amplified by PCR with the primers 5′-GGCCTCTAGACATATGCCTAAATCAAAGG-3′ and 5′-GGCCGGATCCCAGCTTTCTTACTGCGTC-3′, which both incorporated XbaI and NdeI sites at the 5′ end and a BamHI site in place of the stop codon at the 3′ end. After digestion with XbaI and BamHI, the XbaI-BamHI fragment was subcloned into pBluescript II KS(−) (Stratagene) that was digested with XbaI and BamHI to create pBKS(−)-PC4. Then, the coding region of *Schistosoma japonicum* glutathione *S*-transferase (GST) was amplified by PCR from expression vector pGEX2TL(+) by using the primers 5′-GGCCGGATCCCCT ATACTAGGTTATTG-3′ and 5′-GGCCGGATCCAGATCTCAGTCAGTCA TTTTGGAGGATGGTCGCC-3′, which both incorporated a BamHI site at the 5′ end and BglII and BamHI sites at the 3′ end. The amplified PCR product was digested with BamHI, and the derived BamHI-BamHI fragment was inserted into the BamHI site of pBKS(−)-PC4 to create pBKS(−)-PC4-GST. After confirmation of its DNA sequence, the entire PC4-GST coding region was cut out with NdeI and BglII digestion and inserted into the NdeI and BamHI sites of pET3a (TaKaRa). PC4 deletion mutants, either as GST-PC4 or as PC4-GST, were created by using the same strategy and were inserted into the same expression vectors in place of wild-type PC4.

Recombinant GST-PC4 and PC4-GST and their derivatives were expressed in *Escherichia coli* BL21(DE3) p*Lys*S at 30°C for 3 h, and the extract was prepared by sonication in buffer C (20 mM HEPES-KOH [pH 7.9], 10% glycerol, 1 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM DTT) containing 100 mM KCl. After removal of insoluble material by centrifugation, the soluble fraction was used for GST pull-down assays.

GST pull-down assays. Ten microliters of glutathione-Sepharose 4B (Amersham Pharmacia Biotech) was equilibrated with buffer C containing 100 mM KCl and 0.1% Triton X-100 and was incubated with *E. coli* extract containing a GST-fusion protein at 4°C for 1 h. The quantity of each *E. coli* extract was adjusted so that an equal amount of GST fusion proteins could be retained on the resin. In all assays, each GST fusion protein immobilized on glutathione-Sepharose 4B was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to ensure that essentially the same amount of GST fusion proteins was immobilized on each resin. After extensive washing of the resin with the same buffer, either 200 ng of recombinant TFIIH or 240 ng of FLAG-tagged GAL4-VP16 was added to the resin suspended in 100 μl of buffer C, and the mixture was incubated at 4°C for 1 h with constant rotation. After the resin had been washed extensively with the equilibration buffer, the bound proteins were eluted with 10 μl of buffer C containing 1 M KCl and 0.1% Triton X-100. Two microliters of each eluate was separated by SDS–12% PAGE and detected by Western blotting with anti-FLAG M2 antibody (Sigma).

Phosphorylation of PC4-GST. Fifty micrograms of PC4-GST immobilized on 10 μl of glutathione-Sepharose 4B was phosphorylated in reaction mixtures (200 μl) containing 20 mM Tris-HCl (pH 7.5), 50 mM KCl, 10 mM $MgCl_2$, 0.2 mM ATP, and 50 U of casein kinase II (New England Biolabs)/μl at 30°C for 1 h. Phosphorylation of PC4-GST was confirmed by both radiolabeling with [γ-^{32}P]ATP and the mobility change on a SDS–15% polyacrylamide gel.

DNase I footprint assays. The promoter regions that contained GAL4 sites were PCR amplified from pG1HMC2AT, pG3HMC2AT, and pG5HMC2AT by using the primers 5′-GTAAAACGACGGCCAGT-3′ and 5′-CCGGGGATCC GGGGATGAGAGTGAATGATGATAGATTTG-3′. After digestion with EcoRI and BamHI, the PCR fragments were subcloned between the EcoRI and BamHI sites of pUC19 to create pUC19-G1, pUC19-G3, and pUC19-G5, which were then entirely sequenced to rule out the possibility of spurious mutations. The plasmids were digested with PvuI and XbaI, and the DNA fragments containing GAL4 sites were isolated after separation on a 4% polyacrylamide gel. Four picomoles of the DNA fragments were labeled by Klenow fragment (New England Biolabs) by using 50 μCi [α-^{32}P]dCTP. Each labeled DNA fragment was then diluted with the same unlabeled fragment to obtain ~2×10^4 cpm per 24 femtomoles of each fragment.

DNA binding reaction mixtures (25 μl) contained 12 mM HEPES-KOH (pH



C

Transcript	Fold Stimulation	
	+GVP	+GVP, +PC4
2 nt	2.1	3.2
20 nt	3.0	13.0
390 nt	3.5	16.6





FIG. 1. Effect of PC4 on promoter escape. (A) DNA templates used for in vitro transcription analyses. The template pG5HMC2AT contains five GAL4-binding sites upstream of the human immunodeficiency virus TATA box and the initiator from the Ad2 ML promoter fused to a 380-bp G-less cassette. This template produces the 390-nt transcript in the presence of ATP (A), CTP (C), UTP (U), and 3′-*o*-methyl GTP (mG) and the 2-nt transcript (initiation product) in the presence of ATP and CTP. The template pG5HMC2AT+20G, which is identical to pG5HMC2AT except that it contains a guanine residue at the +20 position, produces the 20-nt transcript in the presence of ATP, CTP, UTP, and 3′-*o*-methyl GTP. (B) Effect of GAL4-VP16 and PC4 upon the 390-, 20-, and 2-nt transcripts. All transcription reactions contained general transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) and RNAPII in the presence or absence of GAL4-VP16 and PC4. The transcripts were separated on a denaturing polyacrylamide gel and autographed. (C) The levels of stimulation (*n*-fold) for the 2-, 20-, and 390-nt transcripts. The transcripts were quantified by using Fujix Bas 2000, and stimulation (*n*-fold) was determined for transcripts in the presence of GAL4-VP16 or GAL4-VP16 and PC4 by using the level for the transcript in the absence of GAL4-VP16 and PC4 as the basal level of transcription. (D) Fold stimulation (Fs) for each step of transcription was determined as indicated by using the values of Fs for the 2-, 20-, and 390-nt transcripts shown in panel C. Open bars indicate Fs in the presence of GAL4-VP16, whereas closed bars indicate Fs in the presence of GAL4-VP16 and PC4. For example, a value of 4.1 for Fs (escape) in the presence of GAL4-VP16 and PC4, indicated by a closed bar above "Escape" in the bar graph, was obtained by dividing of Fs (20 nt) (13.0) by Fs (2 nt) (3.2) in the presence of GAL4-VP16 and PC4.

7.9), 6% glycerol, 60 mM KCl, 0.6 mM EDTA, 8 mM $MgCl_2$, 5 mM DTT, the indicated amount of GAL4-VP16, and 24 fmol of the labeled fragment and pUC19, which corresponds to approximately 50 ng of pG5HMC2AT used for in vitro transcription reactions. The reaction mixtures were incubated at 30°C for 60 min, and the DNA fragment was digested with DNase I for 2 min at room temperature by adding 25 μl of 5 mM $CaCl_2$–10 mM $MgCl_2$ containing 0.002 U of DNase I (TaKaRa). The DNase I digestion was stopped by adding 150 μl of stop solution (0.2% SDS, 20 mM EDTA), 20 μg of glycogen, and 5 μg of proteinase K, and the reaction mixtures were further incubated at 37°C for 60 min. After extraction with phenol and chloroform, the DNA fragment was precipitated with ethanol and rinsed twice with 70% ethanol. The dried pellet was redissolved in 2 μl of 90% formamide–0.025% (wt/vol) xylene cyanol and separated on a 4% denaturing polyacrylamide gel.

RESULTS

Promoter escape is a target for the coactivator activity of PC4. To gain a mechanistic insight into the coactivator function in transcriptional activation, we utilized a model in vitro transcription system that included GAL4-VP16 as an activator and PC4 as a coactivator. This in vitro transcription system contained well-defined components, including recombinant factors (TFIIA, TFIIB, TFIIE, TFIIF, TFIIH, PC4, and GAL4-VP16) as well as highly purified HeLa cell-derived FLAG-tagged TFIID and RNA polymerase II (10–12), and exhibited marked transcriptional activation in response to GAL4-VP16 in a highly PC4-dependent manner. These features of this system provided an excellent opportunity to analyze mechanistic aspects of the coactivator function of PC4 in a quantitative manner.

To accurately quantify the effects of PC4, we focused exclusively on measuring the amounts of the 2-, 20-, and 390-nt transcripts (Fig. 1A). We took this approach because measuring the amount of PIC (either by immunoblotting or by gel-mobility shift) and the degree of promoter opening (by potas-

sium permanganate footprinting) did not give sufficiently accurate values compared to measuring the amounts of transcripts and therefore did not provide useful information for detailed quantitative analyses. For this reason, the effects of PC4 on PIC assembly and promoter opening are subsumed in the effects on the 2-nt ApC formation, which corresponds to the initiation step on the templates used in this study (Fig. 1A). Accordingly, unless otherwise stated, the term "initiation," used hereafter for brevity, includes all three steps: PIC assembly, promoter opening, and ApC formation.

Using this reconstituted in vitro transcription system, we measured the levels of the 2-, 20-, and 390-nt transcripts produced from the template pG5HMC2AT or its derivatives (Fig. 1A). The 2-nt initiation transcript, which is ApC on the template pG5HMC2AT, was produced in the presence of ATP and CTP. The 20-nt transcript was produced in the presence of ATP, CTP, UTP, and 3′-*o*-methyl GTP from template pG5HMC2AT+20G, which contained a G residue at the +20 position, at which transcription terminates through incorporation of 3′-*o*-methyl GTP (Fig. 1A). The 390-nt transcript was produced from template pG5HMC2AT in the presence of ATP, CTP, UTP, and 3′-*o*-methyl GTP. After the relative amounts of these transcripts had been determined, the effects of GAL4-VP16 or GAL4-VP16 and PC4 on initiation, promoter escape, and elongation were estimated (Fig. 1B and C). The effect on initiation was estimated directly from the stimulation (*n*-fold) of the 2-nt transcript. Also, the effect on promoter escape was estimated by dividing the stimulation (*n*-fold) of the 20-nt transcript by that of the 2-nt transcript, and likewise, the effect on elongation was estimated by dividing the stimulation (*n*-fold) of the 390-nt transcript by that of the 20-nt transcript.

As shown in Fig. 1B and C, GAL4-VP16 alone stimulated the production of the 2-, 20-, and 390-nt transcripts 2.1-, 3.0-, and 3.5-fold, respectively. Thus, the effects of GAL4-VP16 on initiation, promoter escape, and elongation were calculated as 2.1-, 1.4-, and 1.2-fold, respectively, indicating that GAL4-VP16 stimulated mostly initiation and had lesser effects on promoter escape and elongation (Fig. 1D). Further inclusion of PC4 in these reactions stimulated the production of the 2-, 20-, and 390-nt transcripts 3.2-, 13.0-, and 16.6-fold, respectively (Fig. 1C). Thus, the combined stimulatory effects of GAL4-VP16 and PC4 on initiation, promoter escape, and elongation were 3.2-, 4.1-, and 1.3-fold, respectively, indicating that PC4 augments the ability of GAL4-VP16 to stimulate initiation, promoter escape, and, to a lesser degree, elongation (Fig. 1D). It is notable that the effects of PC4 on the coactivation of GAL4-VP16 are more pronounced at the promoter escape step than at the other steps (Fig. 1D). Taken together, these results not only corroborate a previous demonstration that PC4 acts through the facilitated PIC assembly (13, 21) but also highlight promoter escape as yet another step facilitated by the coactivator activity of PC4.

PC4 requires TFIIA and TAFs for stimulating promoter escape in response to GAL4-VP16. Previous biochemical studies demonstrated that TFIIA and the TAF subunits of TFIID greatly enhance transcriptional activation in vitro. Despite the well-documented roles of TFIIA and TFIID during the assembly of PIC (7, 8, 24, 33), their effects on promoter escape in activated transcription remain undefined. Moreover, observations that TBP alone supports transcriptional activation by various activators, including GAL4-VP16 (39, 43, 59, 64), suggest that some steps may be stimulated without TAFs.



FIG. 2. Requirement of TFIIA and TAFs for stimulation of promoter escape by PC4. Stimulation of the 390-nt (A), 20-nt (B), and 2-nt (C) transcripts in the absence of TFIIA or TAFs. Transcription reactions were done in the absence of TFIIA (−IIA) or the TAF subunits of TFIID by using pG5HMC2AT or pG5HMC2AT+20G. The levels of stimulation of each transcript (*n*-fold) are indicated below the autoradiograms of the gels. In the absence of TFIIA or TAF subunits of TFIID, little stimulatory effect was observed on initiation, promoter escape, and elongation in the presence of GAL4-VP16 or in the presence of both GAL4-VP16 and PC4 except for a small stimulatory effect (i.e., ~2.3-fold) on elongation by PC4 in the absence of TFIIA, an effect that was dependent upon the presence of TFIID.

To determine whether TFIIA and TAFs are required for mediating the stimulation of promoter escape by GAL4-VP16 and PC4, we performed in vitro transcription assays in the presence or absence of TFIIA and TAFs. When TFIIA was removed from the reactions, the 2-, 20-, and 390-nt transcripts were stimulated 1.1-, 1.0-, and 1.3-fold, respectively, in the presence of GAL4-VP16 alone and 1.0-, 1.2-, and 2.7-fold, respectively, in the presence of GAL4-VP16 and PC4 (Fig. 2). Thus, in the absence of TFIIA, there was little stimulation of initiation and promoter escape by PC4 in response to GAL4-VP16. Interestingly, an approximately twofold stimulatory effect on elongation by GAL4-VP16 and PC4 remained intact even in the absence of TFIIA, albeit in a TAF-dependent manner (Fig. 2A and B), although this effect was not pursued further in this study. When TFIID was replaced by TBP, the 2-, 20-, and 390-nt transcripts were stimulated 0.6-, 0.9-, and 1.0-fold, respectively, in the presence of GAL4-VP16 and 1.0-,



FIG. 3. PC4 interacts directly with TFIIH. (A) Interaction of PC4 with TFIIH. PC4 was fused to the C terminus of GST and expressed in *E. coli* as GST-PC4. TFIIH and GAL4-VP16 were allowed to interact with GST or GST-PC4 prebound to glutathione-Sepharose, and, after extensive washing, bound proteins were eluted, separated by SDS-PAGE along with ~20% of the amount of the input protein, and detected by immunoblotting. TFIIH and GAL4-VP16 were detected with anti-FLAG M2 antibody, since the MO15 subunit of TFIIH and GAL4-VP16 were tagged with a FLAG epitope. The positions of molecular mass markers are indicated on the left. The positions of MO15 (TFIIH) and GAL4-VP16 (GVP) are also indicated on the right. (B) Interaction of TFIIH and GAL4-VP16. GST pull-down assays were done under the same conditions as used for the tests presented in panel A, with GST-VP16 being used in place of GST-PC4.



FIG. 4. The interaction of TFIIH and GAL4-VP16 with the coactivator domain of PC4. (A) Schematic representation of the domain structure of PC4. Two serine-rich domains, termed SEAC, are present between amino acid residues 7 and 22 and between residues 43 and 63. The domain for binding single-stranded DNA (dotted line) is localized between residues 63 and 127, and the 89th tryptophan residue is critical for its activity. The coactivator domain (dotted line) is localized to the region between residues 63 and 91, partially overlapping the ssDNA-binding domain. The lower panel shows the tested deletion mutants and the results of the GST pull-down assays for their interactions with PC4 or GAL4-VP16. The 127-amino-acid full-length PC4 is indicated by "wt." Binding and nonbinding are indicated by "+" and "−," respectively, on the right side of the lower panel. (B) GST pull-down assays for PC4 deletion mutants, as detected with Western blots. Note the variation in the amounts of bound TFIIH, which was reproducible, in marked contrast to the constant level of GAL4-VP16 binding.

1.3-, and 1.0-fold, respectively, in the presence of GAL4-VP16 and PC4 (Fig. 2), demonstrating that TAFs are essential for stimulating all of the steps, including initiation, promoter escape, and elongation, at least under the present assay conditions. Together, these observations suggest that both TFIIA and TAFs are indispensable for PC4 to effect noticeable stimulation of promoter escape as well as initiation (probably via facilitated PIC assembly) in response to GAL4-VP16.

PC4 interacts with TFIIH and GAL4-VP16 via its coactivator domain. A previous study showed that TFIIH is required for the stimulation of promoter escape because of its ERCC3 helicase activity (10) in activated transcription by GAL4-VP16 and PC4. The fact that both PC4 and TFIIH are required simultaneously to facilitate promoter escape prompted us to examine a possible physical interaction between PC4 and TFIIH. To do this, we performed GST pull-down assays by using PC4 fused to the C terminus of GST, which was expressed in *E. coli* and retained on the glutathione-Sepharose resin. Since recombinant TFIIH has a FLAG tag at the C terminus of its MO15 subunit and GAL4-VP16 has an N-terminal FLAG tag, both proteins were detected by Western blotting with anti-FLAG M2 antibody after separation by SDS-PAGE. As shown in Fig. 3A, TFIIH was found to bind to GST-PC4 but not to GST alone, indicating that PC4 interacts with TFIIH specifically. The interaction between PC4 and TFIIH seemed as strong as the well-characterized interaction between PC4 and VP16 (Fig. 3A) and that between TFIIH and the VP16 activation domain (Fig. 3B), since similar proportions (~10%) of input TFIIH and GAL4-VP16 were bound to GST-PC4 under the same conditions.

To explore the relevance of the interactions of PC4 with TFIIH and with GAL4-VP16 for the coactivator activity of PC4, we localized the region of PC4 that interacted with TFIIH and GAL4-VP16. We created N-terminal and C-terminal deletion mutants of PC4, as shown in Fig. 4A, and tested their interactions with TFIIH and GAL4-VP16. As shown in Fig. 4B and also summarized in Fig. 4A, the mutants PC4(22-127), PC4(43-127), PC4(63-127), PC4(1-62), and PC4(1-42) interacted with both TFIIH and GAL4-VP16, whereas PC4(92-127), PC4(107-127), and PC4(1-21) did not interact with either TFIIH or GAL4-VP16 (Fig. 4A and B), showing that PC4 interacts with TFIIH and GAL4-VP16 through the region from residue 22 to residue 91, a domain necessary and sufficient for the coactivator activity of PC4 (21, 27). Furthermore, the PC4 mutants PC4(1-62) and PC4(63-127), which do

not overlap with each other, interacted with both TFIIH and GAL4-VP16, suggesting that these interactions occur redundantly at multiple sites within the coactivator domain of PC4. The interactions of the different PC4 mutants with GAL4-VP16 were equally strong, whereas those with TFIIH showed variations; for example, PC4(43-127) interacted with TFIIH more strongly than wild-type PC4 did, while PC4(22-127), PC4(1-62), and PC4(1-42) interacted with TFIIH more weakly than wild-type PC4 did (Fig. 4B).

Thus, colocalization of the interaction region to the functionally defined coactivator domain (21, 27) argues that these interactions are functionally relevant for the coactivator activity of PC4. Moreover, the redundancy of these interactions is consistent with the role of PC4 as a coactivator, which is expected to interact with activators and the basal transcriptional machinery at the same time.

Distinct regulation of the interactions of PC4 with GAL4-VP16 and TFIIH. Since the interaction of TFIIH with PC4 mutants appeared to differ slightly from that of GAL4-VP16, we further explored the difference between these two interactions. The interaction between PC4 and GAL4-VP16 was previously shown to be negatively regulated by phosphorylation of the N-terminal region of PC4 (14, 27); therefore, we sought to determine whether the same was true for the interaction between PC4 and TFIIH. To make this determination, we used PC4-GST, in which the C terminus of PC4 is fused to the N terminus of GST, since GST-PC4 could not be phosphorylated efficiently by casein kinase II, presumably because the N-terminal phosphorylation sites of PC4 within GST-PC4 were sterically inaccessible to the casein kinase II (Fig. 5C). PC4-GST, expressed in *E. coli* and retained on glutathione-Sepharose, showed essentially the same binding to TFIIH and GAL4-VP16 as GST-PC4 did (data not shown). As shown in Fig. 5B, PC4-GST could be readily phosphorylated, and the phosphorylation slowed the migration of PC4-GST on the SDS gel, a shift of migration similar to that observed for nonfused PC4 (Fig. 5A), indicating that PC4-GST was phosphorylated in essentially the same manner as PC4 was. Pull-down assays with PC4-GST indicated not only that TFIIH interacted with both phosphorylated and nonphosphorylated PC4, but also that its interaction with PC4 was slightly enhanced by the phosphorylation of PC4 (Fig. 5D). In marked contrast, the interaction between GAL4-VP16 and PC4 was completely abolished upon phosphorylation of PC4, as reported previously (13, 27). Thus, although TFIIH and GAL4-VP16 interact with PC4 through the same coactivator domain, these interactions show markedly distinct regulation through the phosphorylation of PC4.

The number of GAL4 binding sites determines the degree to which each step of the transcriptional process is stimulated upon activation. The multiple interactions of GAL4-VP16 and PC4 with the basal transcription machinery, as demonstrated here and elsewhere, and the observed stimulatory effects before and after initiation suggest that each GAL4-VP16 dimer bound to the five GAL4 sites may have a distinct role in activated transcription. To gain further insight into a potential relationship between each GAL4-VP16 dimer and the effects on distinct steps, as well as the role of PC4 in this process, we determined the degree to which each step of transcription is stimulated in the presence and absence of PC4 when the number of bound GAL4-VP16 dimers was reduced (Fig. 6A). To



FIG. 5. PC4 interacts with TFIIH in a manner distinct from that of GAL4-VP16. (A) Phosphorylation of PC4 with casein kinase II (CKII). Purified PC4 was phosphorylated by casein kinase II (New England Biolabs), and the shifted mobility of PC4 was observed upon phosphorylation. The positions of phosphorylated PC4 (p-PC4) and nonphosphorylated PC4 (PC4) are shown on the right. (B) Phosphorylation of PC4-GST. The positions of phosphorylated PC4-GST (p-PC4-GST) and nonphosphorylated PC4-GST (PC4-GST) are indicated on the right. (C) As shown schematically, PC4 fused to the N terminus of GST was efficiently phosphorylated by casein kinase II. Casein kinase II phosphorylated PC4 fused to the N terminus, but not to the C terminus, of GST (data not shown), presumably because the phosphorylation sites within the N-terminal region of PC4 were sterically masked by GST. A GST molecule and PC4 are schematically represented, and a phosphate molecule and the amino and carboxyl termini of PC4 are indicated by P, N, and C, respectively. (D) Interaction of phosphorylated PC4 with TFIIH. GST pull-down assays with PC4-GST revealed that TFIIH interacted with both nonphosphorylated and phosphorylated forms of PC4 but that GAL4-VP16 interacted only with the nonphosphorylated form of PC4. Note that approximately twofold more TFIIH bound to p-PC4-GST than to PC4-GST.

this end, we created the templates with one, three, and five GAL4-binding sites (G1, G3, and G5 templates, respectively, binding 2, 6, and 10 GAL4-VP16 dimers) (Fig. 6A) and performed in vitro transcription analyses. As shown in Fig. 6 and quantified in Fig. 7, GAL4-VP16 alone stimulated the level of the 390-nt transcripts from the G1, G3, and G5 templates 2.6-, 2.9-, and 3.5-fold, respectively, showing that increasing the number of bound GAL4-VP16 dimers does not necessarily lead to robust transcriptional activation when PC4 is absent from the reactions. In the presence of PC4, however, stimulation of the 390-nt transcript increased dramatically to 5.3-, 14.3-, and 17.2-fold for the G1, G3, and G5 templates, respectively (Fig. 6B and 7A), revealing that the effect of PC4 becomes more apparent as the number of GAL4-VP16 dimers is increased. Moreover, DNase I footprint analyses showed that



FIG. 6. Effect of the number of GAL4 sites on the degree of stimulation of the 390-, 20-, and 2-nt transcripts. (A) Templates used for in vitro transcription. Three templates, pG1HMC2AT, pG3HMC2AT, and pG5HMC2AT, contained one, three, and five GAL4 binding sites, respectively. For in vitro transcription for 20-nt transcripts, the same set of the templates with a G residue at the +20 position (not shown) was used. The amount of GAL4-VP16 added to the transcription reaction was the same for all reactions (25 ng). (B to D) The effects of one, three, and five GAL4 sites on the stimulation of the 390-nt (B), 20-nt (C), and 2-nt (D) transcripts. G1, G3, and G5 indicate pG1HMC2AT, pG3HMC2AT, and pG5HMC2AT, respectively. (E) Binding of GAL4-VP16 to the G1, G3, and G5 templates. Increasing amounts of GAL4-VP16 were tested for binding to the DNA fragments containing one, three, and five GAL4 sites. The added amounts of GAL4-VP16 were 0 ng (lane 1), 1.6 ng (lane 2), 3.1 ng (lane 3), 6.3 ng (lane 4), 12.5 ng (lane 5), 25 ng (lane 6), and 50 ng (lane 7). The positions of GAL4 binding sites (G1, G3, and G5), the TATA box (TATA), and the initiation site (+1) are indicated on the right.

all of the GAL4 sites on the G1, G3, and G5 templates were occupied almost completely by 25 ng of GAL4-VP16 (Fig. 6E, lane 6), the amount that was used for in vitro transcription reactions. Thus, it is unlikely that transcriptional activation for the G3 and G5 templates derives from the PC4-induced cooperative binding of GAL4-VP16 to its cognate sites. More likely, however, is the possibility that PC4 increases the number, or the effectiveness, of the interactions between GAL4-VP16 and the basal transcription machinery to allow synergistic effects of multiply bound GAL4-VP16 dimers (Fig. 7A).

Next, to determine the relative stimulation of initiation, promoter escape, and elongation in activated transcription from the G1, G3, and G5 templates, we assayed and quantified the amounts of the 2- and 20-nt transcripts from these templates (Fig. 6C and D) and then ascribed the effects of GAL4-VP16 or of GAL4-VP16 and PC4 to three distinct steps (Fig. 7B and C). The analyses of the transcripts from the G1 template in the presence of GAL4-VP16 alone revealed minor stimulation of initiation, with little stimulation of promoter escape and elongation. However, markedly increased levels of stimulation of promoter escape and, to a lesser extent, elongation were observed when PC4 was included in these reactions (Fig. 7C, top panel). Interestingly, no stimulation whatsoever of initiation from the G1 template was observed in the presence of both GAL4-VP16 and PC4 (Fig. 7C, top panel). In contrast, robust activation of transcription from the G3 and G5 templates by GAL4-VP16 and PC4 was attributed largely to the marked stimulation of both initiation and promoter escape (Fig. 7C, middle and bottom panels). Low levels of transcriptional activation for these templates in the presence of GAL4-VP16 alone, however, resulted mainly from the stimulation of initiation.

These data demonstrate the following points. First, GAL4-VP16 alone can effect a low level of stimulation of the initia-